Compare BioNTech SE - ADR (BNTX) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.09. The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | GPTY | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $119.34 | $50.52 |
52-Week Low | $83.89 | $34.73 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
GPTY trades at $43.50, down 2.2% today, with technical indicators showing mixed signals amid neutral overall momentum. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.30-$0.38. Support levels cluster around $43-44 while resistance sits at $45-46. Recent coverage highlights GPTY's focus on AI and tech exposure through option premium strategies, though some analysts question sustainability of current performance levels.
The outlook remains balanced with income generation from weekly dividends offset by technical weakness. Key risks include concentration in tech sector volatility and dependency on option strategy performance. Analyst sentiment appears divided between income-focused appeal and concerns about NAV erosion potential in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
